- Home
- TRMD vs MNKD Comparison
TRMD vs MNKD Comparison
Compare TRMD & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRMD
- MNKD
- Stock Information
- Founded
- TRMD 1889
- MNKD 1991
- Country
- TRMD United Kingdom
- MNKD United States
- Employees
- TRMD N/A
- MNKD N/A
- Industry
- TRMD Marine Transportation
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- TRMD Consumer Discretionary
- MNKD Health Care
- Exchange
- TRMD Nasdaq
- MNKD Nasdaq
- Market Cap
- TRMD 2.0B
- MNKD 1.7B
- IPO Year
- TRMD N/A
- MNKD 2004
- Fundamental
- Price
- TRMD $20.99
- MNKD $5.56
- Analyst Decision
- TRMD Buy
- MNKD Strong Buy
- Analyst Count
- TRMD 1
- MNKD 5
- Target Price
- TRMD $23.00
- MNKD $10.80
- AVG Volume (30 Days)
- TRMD 577.5K
- MNKD 4.6M
- Earning Date
- TRMD 11-06-2025
- MNKD 11-06-2025
- Dividend Yield
- TRMD 12.56%
- MNKD N/A
- EPS Growth
- TRMD N/A
- MNKD 149.32
- EPS
- TRMD 3.31
- MNKD 0.11
- Revenue
- TRMD $1,321,800,000.00
- MNKD $301,736,000.00
- Revenue This Year
- TRMD N/A
- MNKD $16.36
- Revenue Next Year
- TRMD N/A
- MNKD $20.34
- P/E Ratio
- TRMD $6.04
- MNKD $50.55
- Revenue Growth
- TRMD N/A
- MNKD 21.48
- 52 Week Low
- TRMD $13.60
- MNKD $3.38
- 52 Week High
- TRMD $30.20
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- TRMD 50.74
- MNKD 57.30
- Support Level
- TRMD $20.13
- MNKD $5.21
- Resistance Level
- TRMD $20.79
- MNKD $5.90
- Average True Range (ATR)
- TRMD 0.48
- MNKD 0.27
- MACD
- TRMD -0.01
- MNKD -0.02
- Stochastic Oscillator
- TRMD 62.17
- MNKD 69.68
About TRMD TORM plc
TORM PLC operates as a shipping company. The company owns and operates product tankers. It is engaged in the transportation of refined oil products The company transports clean petroleum products including gasoline, jet fuel, naphtha, and diesel oil, as well as other clean products. Its segments include the Tanker segment, and Marine Engineering segment. The company derives maximum revenue from Tanker segment.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.